MET exon 14 (METex14) skipping variants occur in 0.6–4% of non-small cell lung cancer (NSCLC), adenocarcinomas [2,3], and belong to the group of molecular biomarkers whose testing is recommended in international guidelines [4,5]. Here, MET is linked to non-small cell lung carcinoma.